Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24387922 | 0.82 | RPS6KA3 (0.31) | — | |
| SCHEMBL13377140 | 0.81 | GABRA1 (0.31) | GABRA1GABRB2CA1CA2 | |
| SCHEMBL9945872 | 0.80 | CA1 (0.31) | CA1CA2 | |
| SCHEMBL2016761 | 0.80 | EIF4A3 (0.35) | GABRA1GABRB2CA1CA2EIF4A3 | |
| SCHEMBL14295823 | 0.77 | CA1 (0.35) | GABRA1GABRB2CA1CA2EIF4A3 | |
| SCHEMBL26959475 | 0.76 | EIF4A3 (0.38) | GABRA1GABRB2CA1CA2EIF4A3 | |
| SCHEMBL20223463 | 0.76 | BCL2 (0.33) | — | |
| SCHEMBL15082628 | 0.76 | GABRA1 (0.31) | GABRA1GABRB2CA1CA2 | |
| SCHEMBL20223455 | 0.76 | GABRA1 (0.35) | GABRA1GABRB2CA1CA2EIF4A3 | |
| SCHEMBL12446934 | 0.76 | GABRA1 (0.31) | GABRA1GABRB2CA1CA2EIF4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11316118-B2 | Dibenzo[d,B]silole-based reactive mesogens | LOMOX LIMITED (GB) | 2022-04-26 | — | — | US | disclosed |
| EP-3523313-B1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | LOMOX LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| US-20190280223-A1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | LOMOX LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| WO-2018065786-A1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | LOMOX LIMITED (GB) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190280223-A1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | CCNB1, CCNE2, UBE2G2 | GABRA1 2838/4885GABRB2 1836/4885CA1 1789/4885 |
| US-11316118-B2 | Dibenzo[d,B]silole-based reactive mesogens | CCNB1, CCNE2, UBE2G2 | GABRA1 2838/4885GABRB2 1836/4885CA1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.